We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

1 hedge funds and large institutions have $0 invested in Acceleron Pharma in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 325 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 330 → 1 (-329)

100% less funds holding in top 10

Funds holding in top 10: 13 → 0 (-13)

100% less capital invested

Capital invested by funds: $9.13B → $0 (-$9.13B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 325

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-329
Holders Change %
-99.7%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-13
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
325
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$923M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$848M
3
ACA
Avoro Capital Advisors
New York
-$688M
4
BlackRock
BlackRock
New York
-$684M
5
FCM
Farallon Capital Management
California
-$373M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fiera Capital (Canada)
26
Fiera Capital (Canada)
Quebec, Canada
– -$74.2M -431,009 Closed
Artisan Partners
27
Artisan Partners
Wisconsin
– -$73.4M -426,285 Closed
Goldman Sachs
28
Goldman Sachs
New York
– -$72M -418,302 Closed
Invesco
29
Invesco
Georgia
– -$70.4M -408,807 Closed
Charles Schwab
30
Charles Schwab
California
– -$70M -406,459 Closed
VI
31
Versor Investments
New York
– -$69M -401,208 Closed
Franklin Resources
32
Franklin Resources
California
– -$68.8M -399,640 Closed
TCM
33
TimesSquare Capital Management
New York
– -$67.5M -392,500 Closed
PCH
34
Polar Capital Holdings
United Kingdom
– -$67.2K -390,488 Closed
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
– -$66.1M -384,210 Closed
AAM
36
Alpine Associates Management
Florida
– -$61M -354,300 Closed
EP
37
Eversept Partners
New York
– -$60.1M -349,494 Closed
Millennium Management
38
Millennium Management
New York
– -$47.1M -273,520 Closed
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
– -$46.7M -271,291 Closed
Northern Trust
40
Northern Trust
Illinois
– -$43M -250,118 Closed
Citigroup
41
Citigroup
New York
– -$42.8M -248,768 Closed
UBS AM
42
UBS AM
Illinois
– -$40.9M -237,506 Closed
CG
43
Carmignac Gestion
France
– -$38.1M -221,502 Closed
N
44
Nuveen
North Carolina
– -$35.3M -205,187 Closed
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
– -$34.5M -200,476 Closed
NM
46
NWI Management
New York
– -$34.4M -200,000 Closed
Deutsche Bank
47
Deutsche Bank
Germany
– -$31.5M -183,241 Closed
Principal Financial Group
48
Principal Financial Group
Iowa
– -$30.1M -174,802 Closed
Handelsbanken Fonder
49
Handelsbanken Fonder
Sweden
– -$27.5M -159,523 Closed
TD Asset Management
50
TD Asset Management
Ontario, Canada
– -$27.2M -157,892 Closed
1
2
3 4 5

XLRN Hedge Fund Activity: Q4 2021 in Review

1 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2021, worth a combined $0 — down 100% from $9.13B a quarter earlier.

Sellers outnumbered buyers: 325 funds closed out of XLRN and 0 opened new positions — a net loss of 325 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $923M sold.

  • 1 institutional investor held Acceleron Pharma (XLRN) as of Q4 2021, down from 330 in Q3 2021.
  • Funds reported $0 of Acceleron Pharma stock for Q4 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Acceleron Pharma positions in Q4 2021 and 325 closed out, a net change of -325 holders.
  • The largest Acceleron Pharma seller in Q4 2021 was T. Rowe Price Associates, an estimated $923M sold.

Based on aggregated 13F filings for Q4 2021.